RxDoctor Payments Data

Shilen Lakhani, MD

Gastroenterology · Reston, VANPI 1871503599

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Boston Scientific at 25.0% of the total.

$13,624in general payments, 2019–2025

Across 589 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • AbbVie$3K
  • Johnson & Johnson$800
  • Gilead$771
  • Olympus America Inc.$744
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$650
  • plus $5K from 35 others
$75,071in research payments, 2019–2025

Across 20 payments — averaging $3753.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ironwood Pharmaceuticals, Inc$75K

What the payments were for

  • Consulting fees$160%
  • Travel & lodging$6084%
  • Food & beverage$12,95795%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,624 in reported general payments places this provider in the 85th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$284,691
Medicare patients
626
Services billed
6,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide20$12,692
MovantikNaloxegol Oxalate11$4,236
Mesalamine11$3,610
Esomeprazole Magnesium51$2,132
Lubiprostone15$895
Pantoprazole Sodium57$829
Rabeprazole Sodium19$303
Omeprazole12$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,552$12,69220 claims
Redhill Biopharma Inc.Movantik$13$4,23611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Reston

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →